Posted by SLS on September 17, 2015, at 20:14:08
In reply to FDA approves Vraylar for schizophrenia, bipolar, posted by Tomatheus on September 17, 2015, at 17:06:52
Vraylar (cariprazine) is currently in phase III trials for bipolar depression. The results have been encouraging. Pharmacologically, the drug is more like Abilify than Risperdal. I am hoping that cariprazine is more effective to treat the negative symptoms shizophrenia and the anhedonia and amotivation of depression.
Like Abilify, Vraylar will probably be more likely to produce akathisia than are most other atypical antipsychotics. However, it might be less likely to produce movement EPS.
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.- George Bernard Shaw
poster:SLS
thread:1082598
URL: http://www.dr-bob.org/babble/20150901/msgs/1082623.html